Structure Therapeutics (GPCR) Free Cash Flow (2022 - 2026)
Structure Therapeutics (GPCR) posted quarterly Free Cash Flow of $14.1 million for Q1 2026, up 126.4% year-over-year from $6.2 million in Q1 2025, and up 121.12% quarter-over-quarter from -$66.5 million in Q4 2025.
Structure Therapeutics (GPCR) Free Cash Flow (2022 - 2026) Analysis & Trends
Structure Therapeutics' Free Cash Flow history runs 5 years deep, the most recent figure standing at $14.1 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 126.4% year-over-year to $14.1 million; the TTM figure through Mar 2026 stood at -$158.5 million (down 12.57% YoY), while the FY2025 annual figure was -$225.8 million, down 85.55% from the prior year.
- Free Cash Flow for Q1 2026 stood at $14.1 million, up from -$66.5 million in the prior quarter.
- The five-year high for Free Cash Flow was $14.1 million in Q1 2026, with the low at -$66.5 million in Q4 2025.
- The 5-year median for Free Cash Flow is -$20.9 million (2023), against an average of -$27.0 million.
- The sharpest annual moves came in 2025 and 2026: Free Cash Flow plunged 154.86% in 2025, then soared 126.4% in 2026.
- Structure Therapeutics' Free Cash Flow stood at -$12.0 million in 2022, then plunged by 78.85% to -$21.5 million in 2023, then sank by 87.53% to -$40.3 million in 2024, then slumped by 65.29% to -$66.5 million in 2025, then jumped by 121.12% to $14.1 million in 2026.
- Business Quant data shows GPCR's Free Cash Flow at $14.1 million in Q1 2026, -$66.5 million in Q4 2025, and -$51.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Structure Therapeutics | 11.65 Bn | 11.65 Bn | - | -155.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -155.56 Mn |
| Jun 30, 2026 | -155.56 Mn |
| Mar 31, 2026 | 14.05 Mn |
| Mar 31, 2026 | 14.05 Mn |
| Dec 31, 2025 | -66.54 Mn |
| Dec 31, 2025 | -66.54 Mn |
| Sep 30, 2025 | -51.94 Mn |
| Sep 30, 2025 | -51.94 Mn |
| Jun 30, 2025 | -54.11 Mn |
| Jun 30, 2025 | -54.11 Mn |
| Mar 31, 2025 | -53.22 Mn |
| Mar 31, 2025 | -53.22 Mn |
| Dec 31, 2024 | -40.25 Mn |
| Dec 31, 2024 | -40.25 Mn |
| Sep 30, 2024 | -20.38 Mn |
| Sep 30, 2024 | -20.38 Mn |
| Jun 30, 2024 | -26.98 Mn |
| Jun 30, 2024 | -26.98 Mn |
| Mar 31, 2024 | -34.08 Mn |
| Mar 31, 2024 | -34.08 Mn |